Form 8-K - Current report:
SEC Accession No. 0000950170-22-004612
Filing Date
2022-03-25
Accepted
2022-03-25 07:36:39
Documents
14
Period of Report
2022-03-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acst-20220324.htm   iXBRL 8-K 56320
2 EX-99.1 acst-ex99_1.htm EX-99.1 26853
3 GRAPHIC img13613954_0.jpg GRAPHIC 7140
  Complete submission text file 0000950170-22-004612.txt   217911

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acst-20220324_lab.xml EX-101.LAB 13448
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acst-20220324_pre.xml EX-101.PRE 9947
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acst-20220324.xsd EX-101.SCH 2507
8 EXTRACTED XBRL INSTANCE DOCUMENT acst-20220324_htm.xml XML 4713
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 22768238
SIC: 2834 Pharmaceutical Preparations